TY - JOUR
T1 - EXTEND III
T2 - Efficacy and safety of ranibizumab in South Korean and Taiwanese patients with subfoveal CNV secondary to AMD
AU - Kwon, Oh Woong
AU - Lee, Fenq Lih
AU - Chung, Hum
AU - Lai, Chi Chun
AU - Sheu, Shwu Jiuan
AU - Yoon, Young Hee
PY - 2012/10
Y1 - 2012/10
N2 - Background The purpose of this study was to investigate the efficacy and safety of intravitreal ranibizumab 0.5 mg in South Korean and Taiwanese patients with subfoveal choroidal neovascularization (CNV) secondary to agerelated macular degeneration (AMD). Methods This was a 12-month, open-label, single-arm, multicenter, phase III study. Ninety-five patients (Taiwanese: 51; South Korean: 44) were included in the study. Key outcome measures assessed included: mean change in best-corrected visual acuity (BCVA) from baseline to months 4 (primary endpoint) and 12 (secondary endpoint); other secondary endpoints comprising categorized mean change in BCVA from baseline at month 4 and month 12, mean change in BCVA from baseline at month 4 and month 12 per baseline characteristics; and incidence of ocular and non-ocular adverse events and serious adverse events (SAEs) at month 12. Results The mean BCVA change improved significantly (p<0.0001) from baseline to both month 4 (+9.3 letters) and month 12 (+10.1 letters). At month 12, the proportion of patients who gained ≥5, 10, or 15 letters from baseline was 75.8%, 54.7%, and 32.6% respectively. Total and CNV lesion area significantly decreased from baseline (p<0.0001). About 57% of patients showed complete absence of fluorescein leakage atmonth 12.Mean change frombaseline visual acuity scores also increased significantly over time for all subgroups. At month 12, ocular SAEs occurred in 2.1% of patients (out of which one patient [1.1%] experienced endophthalmitis) and 16.8% of patients experienced non-ocular SAEs. There were no deaths reported during the study. Conclusions Consistent with previous studies in Caucasian and Japanese populations, EXTEND III confirms that monthly intravitreal injections of ranibizumab 0.5 mg administered over 12 months is effective and well-tolerated in South Korean and Taiwanese patients with subfoveal CNV secondary to AMD.
AB - Background The purpose of this study was to investigate the efficacy and safety of intravitreal ranibizumab 0.5 mg in South Korean and Taiwanese patients with subfoveal choroidal neovascularization (CNV) secondary to agerelated macular degeneration (AMD). Methods This was a 12-month, open-label, single-arm, multicenter, phase III study. Ninety-five patients (Taiwanese: 51; South Korean: 44) were included in the study. Key outcome measures assessed included: mean change in best-corrected visual acuity (BCVA) from baseline to months 4 (primary endpoint) and 12 (secondary endpoint); other secondary endpoints comprising categorized mean change in BCVA from baseline at month 4 and month 12, mean change in BCVA from baseline at month 4 and month 12 per baseline characteristics; and incidence of ocular and non-ocular adverse events and serious adverse events (SAEs) at month 12. Results The mean BCVA change improved significantly (p<0.0001) from baseline to both month 4 (+9.3 letters) and month 12 (+10.1 letters). At month 12, the proportion of patients who gained ≥5, 10, or 15 letters from baseline was 75.8%, 54.7%, and 32.6% respectively. Total and CNV lesion area significantly decreased from baseline (p<0.0001). About 57% of patients showed complete absence of fluorescein leakage atmonth 12.Mean change frombaseline visual acuity scores also increased significantly over time for all subgroups. At month 12, ocular SAEs occurred in 2.1% of patients (out of which one patient [1.1%] experienced endophthalmitis) and 16.8% of patients experienced non-ocular SAEs. There were no deaths reported during the study. Conclusions Consistent with previous studies in Caucasian and Japanese populations, EXTEND III confirms that monthly intravitreal injections of ranibizumab 0.5 mg administered over 12 months is effective and well-tolerated in South Korean and Taiwanese patients with subfoveal CNV secondary to AMD.
KW - Age-related macular degeneration
KW - Best-corrected visual acuity
KW - Choroidal neovascularization
KW - Fluorescein leakage
KW - Intravitreal ranibizumab
UR - http://www.scopus.com/inward/record.url?scp=84867741992&partnerID=8YFLogxK
U2 - 10.1007/s00417-012-1970-3
DO - 10.1007/s00417-012-1970-3
M3 - 文章
C2 - 22382503
AN - SCOPUS:84867741992
SN - 0721-832X
VL - 250
SP - 1467
EP - 1476
JO - Graefe's Archive for Clinical and Experimental Ophthalmology
JF - Graefe's Archive for Clinical and Experimental Ophthalmology
IS - 10
ER -